Trinity Biotech | TRIB - Cash And Equivalent


Trinity Biotech reported $1.34M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Abbott USD 6.8B 1.72B Mar/2026
Bayer EUR 6.67B 774M Dec/2025
Bio-Rad Laboratories USD 507.2M 22.6M Mar/2026
EDAP TMS EUR 29.84M 4.35M Dec/2024
J&J USD 21.69B 1.98B Mar/2026
Mesa Laboratories USD 28.98M 8.55M Dec/2025
OraSure Technologies USD 176.96M 22.31M Mar/2026
Plus Therapeutics USD 3.02M 1.23M Mar/2026
Roche Holding CHF 7.55B 579M Jun/2025
Siemens EUR 15.26B 768M Dec/2025
Surmodics USD 36.11M 11.81M Sep/2024
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
Tosoh JPY 133.1B 10.44B Sep/2025
Trinity Biotech USD 1.34M 3.83M Sep/2025
Veracyte USD 263.14M 99.44M Mar/2026